Brief: Vir Biotechnology Announces Closing Of Exclusive Worldwide License Agreement With Sanofi For Multiple Potential Best-In-Class Clinical-Stage T-Cell Engagers
09/09/2024 22:27
Vir Biotechnology Inc VIR.O :
* VIR BIOTECHNOLOGY ANNOUNCES CLOSING OF EXCLUSIVE WORLDWIDE
LICENSE AGREEMENT WITH SANOFI FOR MULTIPLE POTENTIAL
BEST-IN-CLASS CLINICAL-STAGE T-CELL ENGAGERS
Source text for Eikon: ID:nBw92vyD3a
Further company coverage: VIR.O
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO